ProMIS Neurosciencesの簿価
ProMIS Neurosciencesの簿価 は何ですか。
ProMIS Neurosciences, Inc.の簿価 は0.53です。
簿価 の定義は何ですか。
1株当たりの帳簿価額は、会社の資産から会社の負債を差し引いた数を発行済株式数で割ったものです。
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
TSXのセクタHealth Careにおける簿価 の企業と比べるProMIS Neurosciences
ProMIS Neurosciencesは何をしますか。
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
ProMIS Neurosciencesと類似の簿価
- Justin Allenの簿価 は0.52です。
- Biofrontera AGの簿価 は0.52です。
- Shrenikの簿価 は0.52です。
- Ngm Biopharmaceuticals Incの簿価 は0.52です。
- ScoZinc Miningの簿価 は0.52です。
- EFT Solutionsの簿価 は0.52です。
- ProMIS Neurosciencesの簿価 は0.53です。
- DATATRAK Internationalの簿価 は0.53です。
- China MeiDong Autoの簿価 は0.53です。
- Alibaba Health Information Technologyの簿価 は0.53です。
- Bamboos Health Careの簿価 は0.53です。
- Interbitの簿価 は0.53です。
- Air France-KLM SAの簿価 は0.53です。